ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Oxford Drug Design Limited

Oxford Drug Design Limited is an active company incorporated on 17 October 2001 with the registered office located in Oxford, Oxfordshire. Oxford Drug Design Limited was registered 24 years ago.
Status
Active
Active since incorporation
Company No
04305857
Private limited company
Age
24 years
Incorporated 17 October 2001
Size
Micro
Turnover is under £1M
Balance sheet is under £500,000
Under 10 employees
Confirmation
Due Soon
Dated 29 October 2024 (11 months ago)
Next confirmation dated 29 October 2025
Due by 12 November 2025 (20 days remaining)
Last change occurred 11 months ago
Accounts
Submitted
For period 1 Jan31 Dec 2024 (1 year)
Accounts type is Total Exemption Full
Next accounts for period 31 December 2025
Due by 30 September 2026 (11 months remaining)
Address
Oxford Centre For Innovation Blue Boar Court
9 Alfred Street
Oxford
OX1 4EH
England
Address changed on 10 Apr 2025 (6 months ago)
Previous address was Oxford Centre for Innovation New Road Oxford OX1 1BY England
Telephone
01865261469
Email
Available in Endole App
People
Officers
7
Shareholders
54
Controllers (PSC)
1
Director • R And D • British • Lives in England • Born in Oct 1958
Director • Ceo • British • Lives in England • Born in Oct 1971
Director • Business Person • Romanian • Lives in Malta • Born in Feb 1961
Director • British • Lives in UK • Born in Jul 1973
Director • Univ Professor • British • Lives in UK • Born in Oct 1939
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Fitzroy Partners Limited
Dr Alan David Roth is a mutual person.
Active
Affinity Drug Design Limited
Paul William Finn is a mutual person.
Active
Oxford Antibiotics Limited
Paul William Finn is a mutual person.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2015–2024)
Period Ended
31 Dec 2024
For period 31 Dec31 Dec 2024
Traded for 12 months
Cash in Bank
£432.12K
Decreased by £111.33K (-20%)
Turnover
Unreported
Same as previous period
Employees
7
Same as previous period
Total Assets
£551.76K
Decreased by £293.74K (-35%)
Total Liabilities
-£265.11K
Increased by £194K (+273%)
Net Assets
£286.65K
Decreased by £487.73K (-63%)
Debt Ratio (%)
48%
Increased by 39.64% (+471%)
Latest Activity
Full Accounts Submitted
2 Months Ago on 6 Aug 2025
Registered Address Changed
6 Months Ago on 10 Apr 2025
William Graham Richards Resigned
8 Months Ago on 12 Feb 2025
Confirmation Submitted
11 Months Ago on 29 Oct 2024
Dr Boris Ayzikovich Appointed
1 Year 1 Month Ago on 17 Sep 2024
Full Accounts Submitted
1 Year 5 Months Ago on 3 May 2024
Confirmation Submitted
1 Year 11 Months Ago on 6 Nov 2023
David Ian Ford Resigned
2 Years Ago on 3 Oct 2023
Full Accounts Submitted
2 Years Ago on 27 Sep 2023
Mr Paul William Finn Details Changed
3 Years Ago on 21 Jul 2022
Get Credit Report
Discover Oxford Drug Design Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Total exemption full accounts made up to 31 December 2024
Submitted on 6 Aug 2025
Second filing of a statement of capital following an allotment of shares on 1 April 2025
Submitted on 20 Jun 2025
Statement of capital following an allotment of shares on 1 April 2025
Submitted on 18 Jun 2025
Resolutions
Submitted on 23 Apr 2025
Solvency Statement dated 01/04/25
Submitted on 23 Apr 2025
Statement by Directors
Submitted on 23 Apr 2025
Statement of capital on 23 April 2025
Submitted on 23 Apr 2025
Registered office address changed from Oxford Centre for Innovation New Road Oxford OX1 1BY England to Oxford Centre for Innovation Blue Boar Court 9 Alfred Street Oxford OX1 4EH on 10 April 2025
Submitted on 10 Apr 2025
Termination of appointment of William Graham Richards as a director on 12 February 2025
Submitted on 24 Feb 2025
Confirmation statement made on 29 October 2024 with updates
Submitted on 29 Oct 2024
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year